Efficacy and safety of sintilimab combined with fruquintinib in treatment of colorectal cancer liver metastasis
Objective To explore the efficacy and safety of sintilimab with fruquintinib in the treatment of colorectal cancer liver metastasis.Methods A total of 90 patients with colorectal cancer liver metastasis admitted to Taizhou Central Hospital from January 2021 to December 2023 were divided into the control group(n=45)and combination group(n=45)randomly.The patients in the control group were given oral fruquintinib capsules and those in the combination group were given intravenous infusion of sintilimab.After 12 weeks of treatment,the clinical efficacy of the two groups was evaluated,and the levels of carcinoembryonic antigen(CEA),carbohy-drate antigen 125(CA-125),and carbohydrate antigen 199(CA-199)in the two groups before and after treatment were compared and re-corded.Gastrointestinal adverse reactions,hand-foot skin reaction,hypertension,elevated aspartate aminotransferase(AST)and protein-uria were also recorded and compared between the two groups.Results After 12 weeks of treatment,the levels of ORR and DCR were significantly higher in the combination group than in the control(20.00%vs 4.44%,88.89%vs 68.89%,χ2=5.075,5.404,both P＜0.05).The levels of CEA,CA-125 and CA-199 were(19.44±2.18)μg·L-1,(35.82±4.66)U·mL-1 and(31.23±4.15)kU·mL-1 in the combination group,which were lower than those of(23.68±2.89)μg·L-1,(40.29±5.07)U·mL-1,(36.49±4.54)kU·mL-1 in the control(t=7.857,4.354,5.737,all P＜0.05).There was no remarkable difference in the occurrence of adverse reactions between the two groups(χ2=0.257,0.476,0.800,0.104,0.304,all P＞0.05).Conclusion Sintilimab combined with fruquintinib has good efficacy in the treatment of patients with colorectal cancer liver metastasis because it can effectively reduce the level of tumor markers but does not increase the incidence of ad-verse reactions.Meanwhile,it is safe and controllable.
SintilimabFruquintinibColorectal cancer liver metastasisEfficacySafety
万方数据
维普
